The effect of octreotide on postoperative adhesion formation.
OBJECTIVE
To investigate the effect of octreotide, a long-acting analogue of somatostatin, on postoperative adhesion formation, because somatostatin inhibits secretion of some growth factors that have modulatory effects on collagen synthesis.


METHODS
An experimental study.


METHODS
Surgical Research and Biochemistry laboratories at Hacettepe University, Ankara, Turkey.


METHODS
Male Swiss albino mice.


METHODS
Both sides of a 5-cm ileal segment from Swiss albino mice were scraped 10 times, and transient ischemia was induced by clamping the segmental artery. Animals were injected subcutaneously with 1 mL/d of saline for 3 days (group 1), a single 5-mL intraperitoneal dose of saline (group 2), subcutaneously with 10 micrograms/kg daily of octreotide for 3 days (group 3) or a single 10 micrograms/kg intraperitoneal dose of octreotide (group 4). In half of the animals repeat laparotomy was performed on postoperative day 5. After adhesions were graded, the scraped ileal segments were excised for determination of hydroxyproline quantity. The same procedure was repeated on postoperative day 14 for the remaining animals.


METHODS
Adhesion grading, hydroxyproline levels.


RESULTS
On postoperative day 5, the intraperitoneal octreotide group (group 4) had a significantly lower median adhesion score than groups 1 and 2. On postoperative day 14, both octreotide groups (3 and 4) had a significantly lower median adhesion grading than both saline groups (1 and 2). Hydroxyproline levels of the groups were not significantly different on either day 5 or day 14.


CONCLUSIONS
Octreotide has a beneficial effect in decreasing adhesion formation in the early postoperative period.
Baykal
A
A
Department of General Surgery, Hacettepe University School of Medicine, Ankara, Turkey. baykal@ceng.metu.edu.tr
Ozdemir
A
A
Renda
N
N
Korkmaz
A
A
Sayek
I
I
D000818:Animals; D003094:Collagen / Q000096:biosynthesis / Q000187:drug effects; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005342:Fibrinolysis / Q000187:drug effects; D006133:Growth Substances / Q000502:physiology; D006909:Hydroxyproline / Q000032:analysis; D007077:Ileal Diseases / Q000145:classification / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D007279:Injections, Subcutaneous; D016014:Linear Models; D008297:Male; D051379:Mice; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000209:etiology* / Q000517:prevention & control*; D012720:Severity of Illness Index; D013997:Time Factors; D000267:Tissue Adhesions / Q000145:classification / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D014945:Wound Healing / Q000187:drug effects
D006133:Growth Substances; D003094:Collagen; D006909:Hydroxyproline; D015282:Octreotide